REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
10.66
-0.07 (-0.61%)
Aug 10, 2026, 10:53 AM EDT - Market open
REGENXBIO Employees
REGENXBIO had 371 employees as of December 31, 2025. The number of employees increased by 18 or 5.10% compared to the previous year.
Employees
371
Change (1Y)
18
Growth (1Y)
5.10%
Revenue / Employee
$470,302
Profits / Employee
-$529,466
Market Cap
703.37M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 371 | 18 | 5.10% |
| Dec 31, 2024 | 353 | 9 | 2.62% |
| Dec 31, 2023 | 344 | -57 | -14.21% |
| Dec 31, 2022 | 401 | 29 | 7.80% |
| Dec 31, 2021 | 372 | 66 | 21.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Phathom Pharmaceuticals | 371 |
| Allogene Therapeutics | 152 |
| Neurogene | 131 |
| BridgeBio Oncology Therapeutics | 106 |
| Cybin | 100 |
| Crescent Biopharma | 69 |
| AgomAb Therapeutics NV | 62 |
RGNX News
- 4 hours ago - Regenxbio price target lowered to $23 from $26 at H.C. Wainwright - TheFly
- 3 days ago - Regenxbio price target raised to $18 from $16 at Morgan Stanley - TheFly
- 3 days ago - Regenxbio downgraded to Equal Weight from Overweight at Barclays - TheFly
- 4 days ago - REGENXBIO Earnings Call Transcript: Q2 2026 - Transcripts
- 4 days ago - REGENXBIO Earnings release: Q2 2026 - Filings
- 4 days ago - REGENXBIO Quarterly report: Q2 2026 - Filings
- 4 days ago - Regenxbio reports Q2 EPS 43c vs. ($1.38) last year - TheFly
- 4 days ago - REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights - PRNewsWire